Cutting Time And Cost In Getting Your Drug To Clinic

A Q&A With Christophe Couturier, VP of Services, Merck Millipore

The challenge of getting your drug product to clinical trials is expensive and time-consuming. This portion of the drug development pipeline could take an average of 18 months to complete — not to mention the sizable investment in facilities and labor. How can pharma and biopharma manufacturers keep new, innovative drugs in the pipeline, and still cut down on those big risk factors?

I recently had an opportunity to talk with Christophe Couturier, VP of Services at Merck Millipore, about how his company is facing these challenges head-on, helping drugmakers streamline their processes.